Clinical Trial Concluded For New Wrinkle Treatment

Clinical Trial Concluded For New Wrinkle Treatment

CosmetaLife clinical trial results could lead to availability of more natural, longer lasting, cost-effective treatment for deep lines and wrinkles by 2009.

St. Paul, Minn. (Vocus) July 24, 2008

Gel-Del Technologies, a St. Paul, Minnesota based biomedical device company announced that it has concluded clinical trials of CosmetaLife, a dermal filler injection that company officials say holds potential to be a more effective alternative to currently available treatments for deep lines and wrinkles that activates a more natural skin correction.

The company began clinical trials of CosmetaLife, a gel-particle product for injection to correct wrinkles, at six U. S. sites in 2006. The company hopes to introduce the product to the rapidly growing $1 billion cosmetic augmentation market in 2009.

David B. Masters, Ph. D., Gel-Del Technologies founder and president, is the inventor of the technology and its related products. Masters said, "It is exciting to see the first human use of this technology over the past 19 months. Based on the results of our 12 month clinical study, CosmetaLife provides a better early performance than hyaluronic acid products, and a lasting effect expected to persist longer due to an actual dermal correction."

Masters continued, "We are pleased with the results of the CosmetaLife trials. As expected, they show our product compares more favorably to Restylane for the first three months and equally to Restylane at the 12-month mark. We are eager to complete the next steps with the FDA."

The proprietary technology used to produce CosmetaLife is covered by 9 U. S. and 26 foreign patents and patent applications. The material is also being developed for fine-line wrinkles and lips, blood vessel grafts, cardiovascular stent coatings, cellular/bone scaffolds, fillers and drug delivery with other uses planned.

"CosmetaLife is just the first in a line of many other important medical applications," said Masters. The company has already been awarded three National Institutes of Health grants to assist it in developing drug delivery devices and artificial blood vessel grafts, based on the same platform technology.

About Gel-Del Technologies
Gel-Del Technologies (www. gel-del. com) is a biomedical device company that makes biomaterial products that mimic the body's tissue using revolutionary and patented protein-based fabrication techniques. David Masters, Ph. D., is the Chief Technology Officer and President of Gel-Del and is the inventor of Gel-Del's technology.

Dr. Masters is internationally recognized as an expert in biomaterials and local drug delivery. Over the past 16 years he has developed several medical products, including implantable medical devices for drug delivery, neurologic, vascular and dermal applications. Dr. Masters received his B. A. in Biochemistry and Biopsychology with Scholar Distinction, a Master's Degree in Chemistry, and a Ph. D. in 1992 in Behavioral and Neural Sciences at Rutgers University, including two awards for excellence in research. He then became a fellow and Instructor at Harvard Medical School Department of Anesthesiology, then Associate Consultant at The Mayo Clinic, Rochester, Minn., and faculty at the University of Minnesota.

Media:
David Ewald
(p) 651-290-6276
(c) 612-490-2650
Davide @ ewald. com

Investors:
David Masters
1000 Westgate Drive
St. Paul MN 55114
(p) 651-209-0762
Dmasters @ gel-del. com

###

HR XCEL Adds DSM To Growing List Of Human Resource Outsourcing Clients

HR XCEL Adds DSM To Growing List Of Human Resource Outsourcing Clients

National HR Outsourcing firm to work with global leader in the pharmaceuticals and biosciences field.

Charlotte, N. C. (PRWEB) September 26, 2006

HR XCEL, LLC, (http://www. hrxcel. com/) an experienced provider of Human Resource Outsourcing, (http://www. hrxcel. com/human-resource-outsourcing. asp) Benefits Administration Outsourcing (http://www. hrxcel. com/benefits-administration. asp) and Payroll Solutions, (http://www. hrxcel. com/payroll. asp) announced today that it will provide Benefits Administration Services for DSM, a global company whose products are used in a wide range of end markets and applications such as human and animal nutrition and health, cosmetics, pharmaceuticals, automotive and transportation, coatings, housing and electrics & electronics (E&E).

DSM has approximately 3,000 employees in the US among their various business units. The company’s global headquarters is headquartered in the Netherlands, with locations in Europe, Asia, Africa and the Americas.

“We chose to partner with HR XCEL due to their unique flexibility and ability to implement a solution that could work in an environment of multiple systems and multiple data feeds,” said Janna Chilton, Director, HR Shared Services. “Additionally, we were impressed with the non-traditional approach to providing benefit services. We didn’t want a typical call-center environment. We wanted our employees to speak to benefits professionals. With

HR XCEL’s approach, their benefits representatives truly become an extension of our HR organization.”

“We recognize that the decision to outsource internal HR functions is a long and intensive process,” said Barbara Sheridan, President and Co-founder, HR XCEL. “Once that decision is made, the vendor selection process is often even more rigorous. We are thrilled that after a diligent process, we have been chosen as the best fit for DSM’s strategic business goals.”

About HR XCEL, LLC.

HR XCEL provides comprehensive Human Resource Outsourcing, Benefits Administration Outsourcing and Payroll Solutions for a wide range of clients and their employees in all 50 states, Canada, Mexico and Puerto Rico. HR XCEL positions clients to focus on their core business lines and activities that generate revenue and profit. Founded by veteran HR professionals, the company is uniquely able to offer clients a high-level of service and HR expertise. For more information, visit www. hrxcel. com.

This press release was distributed through eMediawire by Human Resources Marketer (HR Marketer: www. HRmarketer. com) on behalf of the company listed above.

###

People Suffering from Acute Myelogenous Leukemia Could Possibly Recover a Significant Settlement From Manufacturers of Benzene Products

People Suffering from Acute Myelogenous Leukemia Could Possibly Recover a Significant Settlement From Manufacturers of Benzene Products.

Acute Myelogenous Leukemia has been linked with benzene exposure. Workers who were exposed to benzene and who have been diagnosed with acute myelogenous leukemia may be able to recover damages against manufacturers of benzene products.

Seattle, WA (PRWEB) July 26, 2006

Thousands of people suffering from acute myelogenous leukemia (http://www. phlawfirm. com/practice_areas/benzene. html) may be entitled to significant monetary compensation for damages from manufacturers of benzene containing products. Acute myelogenous leukemia, or AML, is a potentially deadly cancer that has been linked to benzene exposure. Benzene (http://www. phlawfirm. com/practice_areas/benzene-exposure. html) is a well known carcinogen and is found in many products.

High levels of benzene exposure are often found in chemical plant workers, industrial plant workers using solvents, painters, paper and pulp workers, pipe fitters, refinery workers, synthetic rubber production workers, and tire plant workers, just to name a few. Workers employed in these industries seem to be at the highest risk of developing leukemia from benzene exposure. Other industries where workers are at high risk from benzene exposure include adhesive production, pesticide manufacturing, new paper press workers, printers, and gasoline station workers.

Two lawsuits were recently filed in King County Superior Court against manufacturers of benzene containing products on behalf of two Boeing workers who contracted acute myelogenous leukemia as a result benzene exposure on the job. The lawsuits were filed jointly by the Texas law firm Schmidt and Clark and the Seattle, Washington personal injury law firm Paglialunga & Harris, PS. The lawsuits are filed under cause numbers 05-2-37353-9 KNT and 06-2-10994-5 KNT.

The benzene lawsuits allege that the manufacturers of the benzene containing products failed to warn consumers about the serious health risks associated with using their products. Benzene leukemia lawsuits frequently seek unspecified damages, but could seek damages in the millions of dollars for pain and suffering and punitive damages.

According to Seattle lawyer Charles Paglialunga (http://www. phlawfirm. com/), who is investigating benzene leukemia lawsuits nationwide, "These lawsuits seek justice on behalf of people who were trying to do their jobs and were unknowingly exposed to benzene, a known cancer causing substance. The manufacturers of benzene containing products need to be held accountable for their actions. People who developed acute myelogenous leukemia from benzene exposure deserve compensation."

###

Pet Paris® Launches 2006 Pet Couture eCommerce Website

Pet Paris® Launches 2006 Pet Couture eCommerce Website

Pet Paris® (www. petparis. com), an online store, features stylish pet couture.

Phoenix, AZ (PRWEB) May 25, 2006

Pet Paris® luxury pet couture is the ultimate fashion house for discerning pets and their owners. Offering elegant lines of pet apparel and accessories, Pet Paris® is committed to delivering exclusive, irresistibly distinctive fashions for picky pups and kittens.

Pet Paris® offers many lines of apparel, including designer couture, coats, sweaters, t-shirts, dresses, shoes and booties. Luxury pet beds, carriers, collars, harnesses, leashes, and jewelry are designed to suit every pet’s style and every owner’s fashion sensibility. Pet Paris® also offers elegant dinnerware, healthy high end treats, wonderful toys, and spa goodies for even the most pampered pup. Sizes range from extra-extra small to extra large and fit both small and large dogs.

Pet Paris® understands dogs. When a dog lover wants luxury, a pampered pooch wants posh, or a puppy needs something new for play, Pet Paris® is the first and only stop online!

About Pet Paris

Founded in 2005 by Dean Ward, Pet Paris® is the ultimate online boutique providing unique, hand made, and one of a kind pet products and accessories ideal for pampering pets and pet owners. The inspiration: Dean’s engagement trip to Paris, along with the love of their two dogs Gianni and Godiva. From the love of fashion, Paris, Gianni and Godiva, the name Pet Paris®s was born and the life style began. “I’ve loved fashion and dogs all my life, and now I’ve put them together in a life style that is Pet Paris®”, said Dean. “Just as we like to look good wherever we go, so do our pets.” Make sure your pet is in style; make sure your pet shops at www. petparis. com.

Pet Paris

Dean Ward, President

12825 W. Weldon Ave

Avondale, Arizona 85323

623-218-6361 Fax

800-508-4520 toll-free

Contactus @ petparis. com

Http://www. petparis. com/ (http://www. petparis. com/)

###

Detox Foot Patches - A Non-Intrusive Way to Flush Toxins - Bodykind. com

Detox Foot Patches - A Non-Intrusive Way to Flush Toxins - Bodykind. com

Simply Detox foot patches absorb accumulated harmful toxins and waste matter from the body fast, easily, effectively and safely.

(PRWEB) February 12, 2005

The Simply Detox, is a specially designed detox foot patch which can be applied to the feet and body and its name means while sleeping in Japanese. Now available here in the UK through bodykind. com.

Simply Detox Foot patches assist a person to detox in a natural non-intrusive way that is so easy you will wonder how you ever lived without it. Simply Detox foot patches absorb accumulated harmful toxins and waste matter from the body fast, easily, effectively and safely.

In Japan about 1,5 million detox foot patches are sold monthly. In Korea it was chosen as hit product of the year in 2002, and in the USA and Scandinavia it has been a huge success. Already popular in parts of Europe over the past 6 months it has now arrived in the UK.

Simply Detox foot patches are non-invasive and can be used in conjunction with other procedures.

If you have specific symptoms you may apply one or more patches to the area of symptoms and one on the corresponding reflex point on your feet.

All contents copyright Waveney Health, UK distributors of Simply Detox Foot Patches. We would like to thank Waveney Health for the contents of this article.

Tel: 0845 257 4520

Email: info@bodykind. com

Web: www. bodykind. com

###

Online Forum Tackles Little-Known Side Effects of Popular Pharmaceuticals

Online Forum Tackles Little-Known Side Effects of Popular Pharmaceuticals

New, unprecedented online forum allows registered users to share their conventional medicine horror stories and the lessons learned.

Tucson, AZ (PRWEB) May 13, 2006

Truth Publishing is launching an online community forum dedicated to educating consumers about the dangerous side effects of prescription drugs and common medical procedures. Located at http://www. DangerousMedicine. com (http://www. DangerousMedicine. com), the site aims to counterbalance biased information presented in pharmaceutical advertisements by allowing users to post their experiences with popular medications and treatments. On the site, visitors will discover honest, personal stories that illuminate little-known complications of conventional medical practices, and other information not widely available in the mainstream media.

"Most side effects of prescription medicines are written in extremely small print in magazine ads or rapidly listed off during television commercials," said Mike Adams, Truth Publishing spokesperson and chief writer. "As a result, people don't have a thorough understanding of the health risks associated with most drugs. This site provides an education resource where patients can interact with others who have taken a prescribed drug and learn about the true dangers of pharmaceuticals."

Like other Truth Publishing sites, http://www. DangerousMedicine. com (http://www. DangerousMedicine. com) provides an alternative resource for consumers concerned about healthcare practices. Current topics include painkillers, antidepressants, cholesterol drugs, anti-inflammatory drugs, bariatric surgery, heart surgery, dental surgeries and more. Users may also post new forum topics expanding the breadth of information available on the site.

The site officially launched May 10 with 233 preregistered users. To learn more, please visit http://www. DangerousMedicine. com (http://www. DangerousMedicine. com)

About Truth Publishing

Truth Publishing is dedicated to a mission of public service through the creation and distribution of educational materials covering natural health, wellness, environmental responsibility and other topics important to people everywhere. Articles and commentary are published at www. newstarget. com, and books and interviews are published at www. truthpublishing. com.

###

More Than 690,000 Americans Have Already Been Vaccinated Against The Flu This Season, SDI Reports - Cdc Supports Expanded Access To Flu Vaccination

More Than 690,000 Americans Have Already Been Vaccinated Against The Flu This Season, SDI Reports - Cdc Supports Expanded Access To Flu Vaccination

More than 690,000 Americans have already received this season’s flu vaccine from their doctor, according to SDI’s VaccineTrack® data through Sept. 4.

Plymouth Meeting, PA (Vocus) September 9, 2010

More than 690,000 Americans have already received this season’s flu vaccine from their doctor, according to SDI’s VaccineTrack® data through Sept. 4. VaccineTrack® provides syndicated weekly vaccine usage by physicians based on medical office electronic healthcare reimbursement claims data.

The U. S. Centers for Disease Control and Prevention (CDC) recently announced an unprecedented campaign to combat seasonal flu through a universal vaccination strategy. CDC removed many restrictions and currently supports seasonal influenza vaccination for all persons 6 months of age and older based on the recommendation of the Advisory Committee on Immunization Practices, which advises CDC on vaccine issues.

In the 2010/2011 season, vaccine manufacturers are slated to produce more influenza vaccine than ever before. Shipments of influenza vaccine began weeks ahead of most other seasons in anticipation of rapid and wide-ranging vaccine uptake.

“These measures taken by CDC and vaccine manufacturers facilitate public health efforts to make flu vaccines available to all,” said Andrew Kress, CEO of SDI.

SDI tracks vaccine use through a variety of channels, including medical offices. SDI maintains the largest influenza-monitoring program in the United States and has tracked, measured, and forecast the number of people affected by cough, cold, influenza, and other upper respiratory conditions for over 25 years.

Each year in the United States, on average, more than 200,000 people are hospitalized and 36,000 people die from seasonal flu complications. CDC recommends a yearly seasonal flu vaccine as the first and most important step in protecting against seasonal flu.

About SDI

SDI is a leading healthcare market insight and analytics firm. It provides the industry’s most comprehensive de-identified patient-level data to pharmaceutical, biotech, retail pharmacy, and medical device companies, enabling them to better understand the healthcare market. SDI also serves the government and the financial services, media, and consumer packaged goods industries. Founded in 1982, SDI counts the world’s top 50 pharmaceutical and biotech firms as its clients.

###